SCHEMBL23521860

SCHEMBL23521860

Cc1ccc(CNC(=O)c2nccnn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ HPGD P15428 4/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KDM4E B2RXH2 4/20 0.48
▸ HTT P42858 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MMP2 P08253 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ STAT3 P40763 1/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ KDM1A O60341 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29819690 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HPGDL3MBTL1ALDH1A1
SCHEMBL28931232 0.88 KMT2A (0.47) KMT2ASMN1; SMN2HPGDL3MBTL1ALDH1A1
SCHEMBL28931229 0.87 L3MBTL1 (0.56) KMT2ASMN1; SMN2L3MBTL1MAPTCYP3A4
SCHEMBL29536120 0.87 L3MBTL1 (0.56) KMT2ASMN1; SMN2L3MBTL1MAPTCYP3A4
SCHEMBL23521747 0.87 CYP2C19 (0.58) KMT2ASMN1; SMN2HPGDALDH1A1MEN1
SCHEMBL29808056 0.87 CYP2C19 (0.58) KMT2ASMN1; SMN2HPGDALDH1A1MEN1
SCHEMBL23521924 0.86 KMT2A (0.55) KMT2ASMN1; SMN2L3MBTL1ALDH1A1HTT
SCHEMBL29808051 0.86 KMT2A (0.55) KMT2ASMN1; SMN2L3MBTL1ALDH1A1HTT
SCHEMBL28675585 0.86 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1HTTMMP2
SCHEMBL29537243 0.86 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1HTTMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4104902-B1 COMPOUNDS AND MEDICAMENTS USING SAME IRIMAJIRI THERAPEUTICS INC (JP) 2026-05-27 — — EP disclosed
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same IRIMAJIRI THERAPEUTICS INC. (JP) 2023-10-10 — — US disclosed
EP-3838901-B1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES IRIMAJIRI THERAPEUTICS INC (JP) 2023-09-27 — — EP disclosed
EP-4104902-A1 COMPOUND AND DRUG CONTAINING SAME Oita University Institute of Advanced Medicine, Inc. (JP) 2022-12-21 — — EP disclosed
CN-115260193-A Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2022-11-01 — — CN disclosed
CN-115052661-A Compound and drug using the same 株式会社大分大学先端医学研究所 2022-09-13 — — CN disclosed
CN-112839944-B Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2022-08-05 — — CN disclosed
US-20220194942-A1 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME IRIMAJIRI THERAPEUTICS INC. (JP) 2022-06-23 — — US disclosed
US-11292794-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC. (JP) 2022-04-05 — — US disclosed
EP-3838901-A1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES Oita University Institute of Advanced Medicine, Inc. (JP) 2021-06-23 — — EP disclosed
CN-112839944-A Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2021-05-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292794-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same AVPR1B, F12, SDHB KMT2A 2506/4885SMN1; SMN2 342/4885HPGD 1521/4885
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same AVPR1B, AVPR2, F12 KMT2A 1948/4885SMN1; SMN2 228/4885HPGD 1967/4885
US-20220194942-A1 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME AVPR1B, AVPR2, F12 KMT2A 1948/4885SMN1; SMN2 228/4885HPGD 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback